Smad3 Couples Pak1 With the Antihypertrophic Pathway Through the E3 Ubiquitin Ligase, Fbxo32

Area of Science:

• Cardiovascular Biology
• Molecular Cardiology
• Signal Transduction

Background:

• Pathological cardiac hypertrophy is a key precursor to heart failure.
• Mechanisms regulating hypertrophy suppression are not well understood.
• Pak1 (p21-activated kinase 1) role in cardiac hypertrophy requires further elucidation.

Purpose of the Study:

• To investigate the role of Pak1 in regulating cardiac hypertrophy.
• To identify downstream targets of Pak1 involved in suppressing pathological cardiac hypertrophy.
• To explore therapeutic strategies targeting Pak1-mediated pathways.

Main Methods:

• Utilized cardiac-specific Pak1 knockout and overexpression mouse models.
• Induction of cardiac hypertrophy via pressure overload.
• Investigated protein-protein interactions and transcriptional regulation using molecular biology techniques.
• Assessed cardiac function and remodeling through physiological and histological analyses.
• Evaluated the therapeutic effect of Berberine on Fbxo32 upregulation and cardiac function.

Main Results:

• Cardiac-specific deletion of Pak1 led to exacerbated hypertrophy under pressure overload due to impaired Fbxo32 (E3 ligase) upregulation.
• Overexpression of constitutively active Pak1 conferred resilience against pathological hypertrophy.
• Pak1 activation promoted Smad3 binding to the FBXO32 promoter, enhancing its transcription.
• Pharmacological activation of Fbxo32 with Berberine ameliorated cardiac hypertrophy and improved cardiac performance in Pak1-deficient mice.

Conclusions:

• Pak1 signaling, through Smad3-mediated transcriptional regulation of Fbxo32, is critical for suppressing pathological cardiac hypertrophy.
• Fbxo32 is identified as a novel downstream target of Pak1 in the context of cardiac hypertrophy.
• These findings highlight Smad3 and Fbxo32 as potential therapeutic targets for managing cardiac hypertrophy and preventing heart failure.